---
title: "Larimar Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286404170.md"
datetime: "2026-05-14T11:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286404170.md)
  - [en](https://longbridge.com/en/news/286404170.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286404170.md)
---

# Larimar Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.31, beating the estimate of USD -0.5357.

EBIT: As of FY2026 Q1, the actual value is USD -31.12 M.

Larimar Therapeutics, Inc. announced its financial results and operational highlights for the first quarter ended March 31, 2026; however, specific financial figures for revenue, net income, cash flow, or operational metrics were not detailed within this filing.

#### Cash and Investments

Larimar Therapeutics, Inc. reported $200.4 million in cash and investments as of March 31, 2026, with a projected cash runway extending into Q2 2027.

#### Operational Highlights

Larimar Therapeutics, Inc.’s nomlabofusp program received FDA Breakthrough Therapy Designation, along with multiple global regulatory designations including US Orphan Drug, Fast Track, and Rare Pediatric Disease designations, as well as EU Orphan Drug and PRIME designations. Clinical evidence from an open-label study showed 100% (10⁄10) of participants with 6-months of data achieved FXN levels similar to asymptomatic carriers, with consistent directional improvement across key clinical outcomes after 1-year of treatment. Approximately 8,000 doses of nomlabofusp have been administered to 65 total participants across all studies, with long-term daily dosing generally well tolerated despite some participants experiencing mild/moderate local injection site reactions or anaphylaxis that was reversed with standard treatment. The company holds a strong intellectual property portfolio for nomlabofusp (CTI-1601), with composition of matter patent extending into 2040 and additional IP protections into 2041, 2043, and 2045, anticipating 12 years of market exclusivity upon US approval and at least 10 years upon EU approval.

#### Outlook and Guidance

Larimar Therapeutics, Inc. intends to initiate a rolling Biologics License Application (BLA) seeking accelerated approval, with nonclinical and clinical modules planned for submission in June 2026, and final modules, including the Chemistry, Manufacturing, and Controls (CMC) module, expected in the second half of 2026. The company plans for a U.S. launch in the first half of 2027, if approved. Key near-term milestones for Q2 2026 include topline data from the Open Label study, an FDA Type B meeting, and the initiation of screening for a Global Confirmatory Phase 3 study, with the first patient expected to be dosed mid-2026.

### Related Stocks

- [LRMR.US](https://longbridge.com/en/quote/LRMR.US.md)

## Related News & Research

- [Larimar Shareholders Approve Governance and Capital Structure Changes](https://longbridge.com/en/news/286968564.md)
- [Larimar Therapeutics Q1 net loss widens slightly R&D expenses fall](https://longbridge.com/en/news/286404964.md)
- [MAA Announces Quarterly Common Dividend | MAA Stock News](https://longbridge.com/en/news/286961140.md)
- [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md)
- [Hemab Therapeutics Reports First Quarter 2026 Financial Results](https://longbridge.com/en/news/287208997.md)